Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
Summary
This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 (pamiparib) (versus placebo) will improve progression-free survival (PFS) in participants with advanced or inoperable gastric cancer.
Timeline
- Start
- 2018-07-03
- Primary completion
- 2020-06-18
- Completion
- 2023-01-03
Outcome
Missed primary endpoint
registry analysis (superiority test); Pamiparib vs Placebo; p = 0.1428; Log Rank NCT03427814 ↗
release “Pamiparib showed numerically higher progression-free survival in patients with gastric cancer compared to placebo, although the results did not achieve statistical significance” beonemedicines.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pamiparib | Small molecule | 60 mg | Oral |